Etiometry, Leading Intensive Care Clinical Decision-Support Software, Achieved Record Growth in New Relationships, Beds Served

2020 growth fueled by expansion into adult and pediatric care settings and the approval of an additional algorithm to power clinical decision-support software

BOSTON–(BUSINESS WIRE)–Etiometry, a leader in clinical decision-support software for the intensive care environment, today, announced significant business growth and expansion in 2020. Clinicians in the intensive care setting rely on patients’ vital signs to monitor for unexpected health events. Etiometry’s software aggregates the information from multiple sources into one streamlined format to assist clinicians in understanding the evolving clinical risks and in making data-driven decisions.

In 2020, Etiometry expanded its existing footprint with pediatric and cardiac intensive care units and extended into both neonatal and adult ICU settings. As a result, the company recorded an increase of 111% in contracted intensive care units. Additionally, Etiometry increased its hospital relationships and is now in more than 20 of the top children’s hospitals in the country, according to U.S. News & World Report. In combination with new clients and the growth of existing relationships, Etiometry experienced an 87% increase in the total number of licensed beds it supports.

“The growth we’ve seen this year is remarkable, and a testament to the important role the software plays in helping clinicians make critical, patient care decisions,” said CEO Shane Cooke. He added, “We are in awe that the healthcare community had the fortitude and vision to both respond to the challenges presented by COVID-19 while simultaneously implementing cutting-edge, innovative technology. We are honored to support the industry on this journey to capture a complete picture of each patient and provide meaningful, actionable data to inform life-changing care.”

Additionally, in 2020, Etiometry obtained its sixth 510(k) clearance from the FDA. This clearance will provide flexibility to adjust index thresholds to achieve individualized patient risk assessment based on their condition and needs. The clearance will also provide further insight by building on the 100 million hours of patient data Etiometry has collected. This information will further drive refinement in the care algorithms used to identify the possibility of deterioration or additional medical events. Also included is Etiometry’s Surveillance View, which provides remote unit-wide viewing of patients on a single display.

“These additional clearances from the FDA will allow Etiometry to continue the momentum into 2021 and beyond,” said Chief Technology Officer and Co-founder, Dimitar Baronov. “The sixth clearance will give Etiometry the ability to broaden the patient conditions monitored allowing for further clinical utilization of the platform. Being able to detect medical incidents prior to the occurrence is crucial to the recovery of a patient. With the new flexibility to accommodate different patient conditions and the increased transparency of our indices, we have a steppingstone into new markets and effective drivers for further clinical utilization that broaden the benefits of the Etiometry Platform.” explained Baronov.

Etiometry continues to be a vital asset to clinical research projects around the world. The platform is easy-to-use for research, and the growing consortium of centers has fostered numerous multi-center projects aimed at improving care through better use of data. More than 150 abstracts were submitted to Pediatric Cardiac Intensive Care Society’s 16th Annual International Meeting in December 2020. Among the top five research presentations was findings on “Performance of a Predictive Analytic Tool (Index of Tissue Oxygen Delivery ‘IDO2’) in Pediatric Cardiac Intensive Care Unit of a Developing Country” by Dr. Qalab Abbas from Aga Khan University Hospital in Karachi, Pakistan.

Etiometry is also committed to assisting researchers by coordinating and providing data management services. One key study in 2020, funded by the National Institutes of Health, has culminated into a multi-center, randomized, prospective clinical trial to evaluate the role of analytics in weaning patients from vasoactive support.

About Etiometry

Etiometry is the leader in clinical decision-support software for the intensive care environment to assist clinicians in making decisions for their patients driven by data. The company’s technologies provide valuable clinical insight and analysis to support early recognition of subtle changes in patient conditions to avoid complications and speed recovery. Etiometry is committed to improving patient outcomes, increasing clinical efficiency, and lowering costs of care through the more effective use of all available data. To learn more, visit www.etiometry.com.

Contacts

Media Contact
Elizabeth Schroll

978-764-2317

[email protected]